Droga Raia - Apresentação de Resultados English
Transcription
Droga Raia - Apresentação de Resultados English
Droga Raia 2010 Financial Results March 30th, 2010 Highlights of the Period Concluded our IPO on Dec. 16th, 2010 with full exercise of the greenshoe in Jan. 10th, 2011. Offer totalled R$ 654 million (R$ 526 million primary). The gross amount received in 2010 that corresponded to the base offer totalled R$ 502 million. Ended 2010 with 350 stores and as Brazil’s 2nd largest chain according to ABRAFARMA. Opened 53 stores and closed 2 stores (24 openings in 4Q10), including 14 stores in nine cities in the countryside of Paraná where we entered in 2010; Gross revenues reached R$ 1.86 billion in 2010, a 16.6% growth of over 2009. (R$ 437 million in 4Q10, a 16.5% growth over the 4Q09); EBITDA reached R$ 75.8 million in 2010, with a margin of 4.1% of gross revenues, a 32.4% growth over 2009 (R$ 18.5 million in 4Q10, 3.6% of gross revenues); Positive net income of R$ 1.7 million in spite of the pressures entailed by depreciation and financial expenses, which derive from an asset base that, at the end of 2010, included only 56% of mature stores; Generated a cash flow from operations of R$ 75.0 million, which allowed us to fund the R$ 84.8 million in total investments undertook in 2010; Established a Training Center in São Paulo and our second distribution Center in Paraná, which will supply our stores in the south of Brazil. This DC has a footprint of 6 thousand square meters and operated in full from the end of December. Adopted IFRS and new GAAPs without economic effects in 2010. Reclassification of Other Op. Revenues into COGS and of incident taxes from sales expenses into COGS. Gross margin decreased 0.6%, fully offset by a reduction in sales expenses. 2 Our IPO totaled R$ 654.7 million. Primary proceeds amounted to R$ 525.7 million, which net of tranasaction expenses, resulted in an equity increase of R$ 500.3 million Base Offer 23/12/2010 Green Shoe 13/01/2011 Total Gross IPO Proceeds 569.3 85.4 654.7 Gross Secondary Offer 67.0 62.1 129.0 Gross Primary Offer (Raia) 502.3 23.3 525.7 Expenses Banking Fees (1) Transaction expenses 24.5 19.1 5.4 0.9 0.9 25.4 20.0 5.4 Net Proceeds (Raia) 477.8 22.4 500.3 (In R$ million) (1) Refer to auditing, lawyers, consulting and other expenses 3 Our IPO will allow us to accelerate our growth program, with a store opening guidance of 60 new stores in 2011 and 90 new stores in 2012. Accelerated Growth Foundations for Growth 1,860 1,595 IPO 1,148 829 721 645 558 467 327 370 95 105 120 132 137 150 198 259 299 350 410* 500* 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011E* 2012E* Stores Gross revenues (R$ million) * Assumes our gross store opening guidance, disregarding eventual store closings that may happen throughout the period. 4 We turned into Brazil’s second largest drugstore chain in store count and remained as the fifth largest in revenues. At the end of December, 44% of our stores were still maturing. ABRAFARMA Ranking - 2010 Store Portfolio Age Distribution – December, 2010 (store count. % of existing stores) Store Count Gross Revenues Year 1 (52 stores) 14.8% 1st Year 2 (41 stores) 11.8% 2nd 3rd Mature (196 stores) 56.0% Year 3 (61 stores) 17.4% 4th 5th Source: ABRAFARMA (considers Drogaria São Paulo’s gross revenues at a Pro-forma basis, because it includes the revenues of Drogão, acquired in June 2010, for the whole year) 5 The Brazilian pharmaceutical and hygiene and personal care markets kept growing at a very fast pace in 2010 Hygiene and Personal Care market growth Pharmaceutical market growth (R$ billion) (R$ billion) 12.7% 19.9% (13.8% of the comparable base) 36.2 27.5 1.8 24.4 21.7 19.6 17.5 15.4 34.4 30.2 26.4 23.6 21.5 19.2 2005 Source: IMS Health 2006 2007 2008 2009 2010 2005 2006 2007 2008 2009 2010 Source: ABIHPEC 6 We accelerated our growth program in 2010. We ended the year with a total of 350 stores and with market share growth in all the top five Brazilian states in which we operate. Total: 350 stores Market Share - Brazil* 2.8% Market Share by State 2.6% 2.4% 2.7%* (December 2010) 3.2% 3.5% 3.8% 4.1%* SP: 246 stores Greater São Paulo: 118 stores • Countryside: 128 stores • 9.0% MG: 22 stores • Greater BH: 22 stores 9.3%* 8.1% 6.9% Minas Gerais São Paulo Paraná Santa Catarina Rio Grande do Sul 0.5% 66.6% of the Brazilian pharmaceutical market 0.0% RS: 9 stores • Greater Porto Alegre: 9 stores RJ: 39 lojas Rio de Greater Rio: 36 stores • Countryside: 3 stores Janeiro 4.3%* 3.8% 3.1% 3.6% • PR: 33 stores • Greater Curitiba: 19 stores 5.4%* • Countryside: 14 stores 4.2% 4.0% 3.3% 0.8%* 0.5% Dec-10 Dec-09 Dec-08 Dec-07 Distribution Center * 2010 participation adjusted to cover the same informant base of 2009. Considering the new base of informants we would have 3.8% of national participation and 8.8% SP; 4.2% RJ; 2.3% MG; 5.2% PR; and 0.8% RS 7 Our gross revenues grew 16.7%, and the highlights have been hygiene and personal care and our comeback in generics sales in the 4Q10. Gross Revenues Sales Mix (R$ million) 2010 vs. 2009 16.7% 1,860.1 38.9% 1,594.6 1,147.6 Personal Care 26.5% OTC 19.9% Generic Medicines 9.6% 27.8% 28.9% 30.2% 30.8% 21.3% 19.3% 19.1% 18.5% 18.1% 15.2% 9.3% 9.3% 9.0% 9.3% 16.5% 509.2 436.9 2008 2009 2010 4Q 2009 4Q 2010 Branded 44.0% Medicines 43.5% 2008 2009 42.7% 2010 42.3% 41.7% 4Q 2009 4Q 2010 14.4% 8 We maintained in the 4Q10 a revenue growth below our historical levels, due to the extraordinary growth produced by the credit crisis and by the swine flu pandemic in 2009. Growth – Total Sales 38.9% 38.5% Growth – Same Stores 22.5% Growth – Mature Stores 21.9% 13.5% 12.6% 32.4% 14.2% 9.0% 20.5% 16.7% 10.3% 16.6% 15.3% 14.8% 6.6% 6.3% 3.8% 4.5% 4.2% 1.6% 0.9% 2008 2009 2010 4Q09 1Q10 2Q10 3Q10 4Q10 2008 2009 2010 4Q09 1Q10 2Q10 3Q10 4Q10 2008 2009 2010 (0.6)% (1.0)% 4Q09 1Q10 2Q10 3Q10 4Q10 9 We expanded our gross margin and sustained a lean cash cycle under a purchasing model that relied, until the end of 2010, on large payment terms from our main suppliers Cash Cycle Gross Profit (days of COGS, days of gross revenues) (R$ million, as % of Gross Revenues) 24.6% 23.7% 24.5% 97.1 23.3% 22.5% 88.3 83.6 28.0% 83.9 78.6 76.3 458.2 72.1 68.9 32.0% 358.0 61.8 56.7 271.4 101.8 124.8 21.8 7.1 2008 2009 Gross Profit 2010 4Q 09 4Q 10 Other Operational Revenues 2008 Receivables 20.9 20.6 19.0 7.4 4.0 2009 18.8 6.8 3.5 2010 Inventories 4Q 09 Suppliers 4Q 10 Cash Cycle 10 Our expense absorption worsened in 2010 due to the low growth of our mature stores and to the acceleration of our store openings. Pre-operational expenses of R$ 1.2MM at the new DC. Sales & Other Op. Expenses – R$ Million Sales & Other Op. Expenses – % of Gross Revenues 298.0 5.6 15.9% 0.1% 16.0% 15.2% 0.3% 0.3% 15.0% 0.5% 242.1 4.9 16.3% 0.5% 182.6 1,2 292.5 15.8% 14.9% 15.7% 14.5% 237.2 15.7% 181.4 65.7 2.3 63.4 2008 2009 Sales Expenses 2010 4Q09 Other Op. Expenses 4Q10 2008 2009 2010 Sales Expenses 4Q09 82.8 2.6 80.1 4Q10 Other Op. Expenses 11 G&A also affected by the low revenue growth and by the upgrade in our logistics structure. Executive bonus of R$ 2.3MM in excess of the existing provision in the 4Q10. Administrative Expenses – R$ thousand Administrative Expenses – % of Gross Revenues 84.4 4.6% 4.5% 4.5% 4.4 % 69.4 0.7% 3.6% 10.7 52.8 0.7% 3.7% 58.7 2.9% 23.1 15.9 3.0 23.1 12.9 2008 2009 Admin. Expenses 2010 4Q 09 Adjustments 4Q 10 2008 2009 Admin. Expenses 2010 4Q 09 4Q 10 Adjustments One-time adjustments: R$ 8.5 million of retroactive recovery in PIS and COFINS and R$ 2.2 million in credits due to changes in the provisioning methodology for civil, tax, and labour contingencies (R$ 3.0 million in the 4Q10) 12 We kept expanding our EBITDA margin in spite of the 4Q10, which was hurt by our worse expense absorption and by R$ 3.5 million in punctual expenses (0.7% of gross revenues) EBITDA (R$ million, as a % of Gross Revenues) 5.4 4.1 3.6 75.8 3.1 3.6 57.2 - DC PR: R$ 1.2 mm (pre operational) - Executive Bonus: R$ 2.3 mm 10.7 - T OTAL: R$ 3.5 mm (0.7% of gross revenues) 36.1 46.5 23.6 3.0 18.6 20.6* 2008 2009 2010 4Q 09 4Q 10 EBITDA Adjustments Adjustment related to the PIS and COFINS credit recovery of R$ 8.5 million and the change in the provision methodology for civil, tax and labour contingencies (equivalent to R$ 2.2 million in the year and R$ 3.0 in the 4Q10) 13 Net income was only slightly positive as a result of our strong growth pace, which pressured depreciation and financial expenses arising from an asset base with 46% of maturing stores Depreciation Net Financial Expenses (R$ million, as a % of Gross Revenues) Net Profit (R$ million, as a % of Gross Revenues) (R$ million, as a % of Gross Revenues) 2.0 2.4 2.2 2.3 2.3 1.6 2.1 1.4 1.5 42.3 1.4 1.3 34.6 0.1 30.1 (0.2) 0.1 (0.9) 27.9 23.0 21.5 11.7 9.1 7.7 5.6 2008 2009 2010 4Q09 4Q10 2008 2009 2010 4Q09 6.1 4Q10 2008 2008 1.6 1.7 2009 2010 (0.9) 4Q09 4Q10 (10.1) 14 We generated R$ 75.0MM of operating cash flow, including R$ 37.3MM in recovered taxes and R$ 30.1MM in interest expenses, which financed the bulk of our R$ 84.8MM investments 15 Our stock has outperformed both the IBOVESPA and the ICON (Consumption Index) since our IPO RAIA IBOV ICON 108,33 99,34 100 Number of Shares (in thousands) Stock quote (R$) (March 25th) Market Cap (R$ million) 62.014 26,0 1.612,4 25-mar 18-mar 11-mar 4-mar 25-fev 18-fev 11-fev 4-fev 28-jan 21-jan 14-jan 7-jan 31-dez 24-dez 17-dez 97,18 Ongoing Actions – March 29th, 2011 We opened three stores in the 1Q11 and signed contracts to open another 25 in 2011; Prepared our entry into Santa Catarina, where we already have contracts to open five stores, which will position us in six of the seven largest states in Brazil that account for 70% of the Brazilian pharmaceutical market; Improved gross margins by reducing payment terms and by selectively investing in inventories for opportunistic purchases Increased our inventory levels in March to profit in the 2Q11 from the annual pharmaceutical price increase Expanded our main Distribution Center, in the São Paulo metropolitan region, from 14 thousand to 19 thousand square meters, in order to cope with the Chain’s expected growth; Signed an agreement to open a Distribution Center in Rio de Janeiro, in the city of Barra Mansa, which is scheduled for the beggining of 2012 (8 thousand square meters); Started several inititives to improve our productivity, including our service levels and service standards; Renegotiated the credit letter that guarantees our loan with BNDES so as to reflect our new capital structure and to reduce our interst expenses from the 2Q11; We hired Itaú DTVM as our market maker, aiming at enhancing our shares’ liquidity; Obtained coverage by five intitutions: Banif, BB Investimentos, Credit Suisse, Itaú BBA, Raymond James. Their average target price for RAIA3 is of R$ 34.00 with a consensus EBITDA of R$ 104.4 million for 2011. 17
Similar documents
Raia Drogasil S.A.
market share of only 8.7% (Sep’11). Recently announced the entrance into 3 new states (MS, MG and BA); Differentiated business model with a dual brand strategy, high returns on invested capital, ...
More information